PD168393 is an irreversible EGFR inhibitor.

Osimertinib is a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity.

Crenolanib is a potent and selective inhibitor of PDGFRα/β.

CP-673451 is a selective inhibitor of PDGFRα/β.

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor.

SU11274 is a selective Met inhibitor.

SGX-523 is a selective Met inhibitor.

BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.